|
44
|
110
|
7l9gA |
Crystal structure of the second bromodomain (bd2) of human brd2 bound to bi2536 |
|
0
|
7
|
7lkyI |
Crystal structure of phf1 tudor domain in complex with a peptidomimetic ligand unc6641 |
|
13
|
56
|
7lkyA |
Crystal structure of phf1 tudor domain in complex with a peptidomimetic ligand unc6641 |
|
33
|
105
|
7la9A |
Crystal structure of the first bromodomain (bd1) of human brd4 (brd4-1) in complex with bivalent inhibitor nc-iii-49-1 |
|
45
|
127
|
7l9mA |
Crystal structure of the first bromodomain (bd1) of human brd4 in complex with bivalent inhibitor gxh-ii-083 |
|
105
|
305
|
7u9yA |
Wdr5 bound to 2-(3,5-dimethoxybenzyl)-7-((2-methyl-1h-imidazol-1-yl)methyl)-5-(1-methyl-3-(trifluoromethyl)-1h-pyrazol-4-yl)-3,4-dihydroisoquinolin-1(2h)-one |
|
102
|
304
|
7uasA |
Discovery of potent orally bioavailable wd repeat domain 5 (wdr5) inhibitors using a pharmacophore-based optimization |
|
41
|
122
|
7t0sA |
Crystal structure of the bcl6 btb domain in complex with oicr-11864 |
|
40
|
123
|
7t0tA |
Crystal structure of the bcl6 btb domain in complex with oicr-10562 |
|
42
|
122
|
7t0uA |
Crystal structure of the bcl6 btb domain in complex with oicr-12387 |
|
38
|
122
|
7ruwA |
Crystal structure of the bcl6 btb domain in complex with oicr-7859 |
|
42
|
122
|
7ruxA |
Crystal structure of the bcl6 btb domain in complex with oicr-8311 |
|
42
|
123
|
7rv1A |
Crystal structure of the bcl6 btb domain in complex with oicr-8826 |
|
44
|
122
|
7rv0A |
Crystal structure of the bcl6 btb domain in complex with oicr-8446 |
|
41
|
122
|
7ruyA |
Crystal structure of the bcl6 btb domain in complex with oicr-8388 |
|
41
|
122
|
7ruzA |
Crystal structure of the bcl6 btb domain in complex with oicr-8445 |
|
43
|
122
|
7rv2A |
Crystal structure of the bcl6 btb domain in complex with oicr-8828 |
|
88
|
240
|
7rrxA |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-19 |
|
88
|
252
|
7rs2A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-23 |
|
85
|
239
|
7rs8A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-16 |
|
91
|
247
|
7rs4A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-8 |
|
88
|
249
|
7rs7A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-30 |
|
91
|
242
|
7rs0A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-18 |
|
85
|
241
|
7rrzA |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-30 |
|
87
|
242
|
7rs3A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-29 |
|
90
|
243
|
7rs9A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-25 |
|
88
|
244
|
7rryA |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-20 |
|
86
|
242
|
7rs1A |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-21 |
|
84
|
240
|
7rs8D |
Crystal structure of the er-alpha ligand-binding domain (l372s, l536s) in complex with dmeri-16 |
|
48
|
225
|
6cdyA |
Crystal structure of tead complexed with its inhibitor |
|
47
|
225
|
6uybA |
Crystal structure of tead2 bound to compound 1 |
|
185
|
552
|
6nuqA |
Stat3 core in complex with compound si109 |
|
183
|
552
|
6njsA |
Stat3 core in complex with compound sd36 |
|
98
|
268
|
6o67A |
Crystal structure of human ppargamma ligand binding domain in complex with mitoglitazone |
|
91
|
270
|
6o68A |
Crystal structure of human ppargamma ligand binding domain in complex with ciglitazone |
|
38
|
127
|
6mh1A |
Crystal structure of the first bromodomain of human brd4 in complex with hu-10, a 1,4,5-trisubstituted imidazole analogue |
|
0
|
4
|
5x54C |
Crystal structure of the keap1 kelch domain in complex with a tetrapeptide |
|
0
|
4
|
3pslC |
Fine-tuning the stimulation of mll1 methyltransferase activity by a histone h3 based peptide mimetic |
|
42
|
109
|
6moaA |
C-terminal bromodomain of human brd2 in complex with 4-(2-cyclopropyl-7-(6-methylquinolin-5-yl)-1h-benzo[d]imidazol-5-yl)-3,5-dimethylisoxazole inhibitor |
|
41
|
114
|
6mo7A |
N-terminal bromodomain of human brd2 with n-((4-(3-(n-cyclopentylsulfamoyl)-4-methylphenyl)-3-methylisoxazol-5-yl)methyl)acetamide inhibitor |
|
41
|
114
|
6mo9A |
N-terminal bromodomain of human brd2 in complex with n-cyclopentyl-7-(3,5-dimethylisoxazol-4-yl)quinoline-5-sulfonamide inhibitor |
|
42
|
114
|
6mo8A |
N-terminal bromodomain of human brd2 in complex with 4,4'-(quinoline-5,7-diyl)bis(3,5-dimethylisoxazole) inhibitor |
|
97
|
268
|
6md2A |
Crystal structure of human ppargamma ligand binding domain in complex with gw9662 and arachidonic acid |
|
98
|
268
|
6md4A |
Crystal structure of human ppargamma ligand binding domain in complex with rosiglitazone and oleic acid |
|
76
|
333
|
6e3sB |
Crystal structure of the heterodimeric hif-2 complex with antagonist pt2385 |
|
68
|
328
|
6e3tB |
Crystal structure of the heterodimeric hif-2 complex with antagonist t1001 |
|
57
|
361
|
6e3tA |
Crystal structure of the heterodimeric hif-2 complex with antagonist t1001 |
|
41
|
127
|
6dmjA |
A multiconformer ligand model of inhibitor 53w bound to creb binding protein bromodomain |
|
42
|
127
|
6dmlA |
A multiconformer ligand model of 3,5 dimethylisoxaxole bound to the bromodomain of human brd4 |
|
40
|
113
|
6dmkA |
A multiconformer ligand model of an isoxazolyl-benzimidazole ligand bound to the bromodomain of human crebbp |
